354 related articles for article (PubMed ID: 17177909)
1. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
4. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
[TBL] [Abstract][Full Text] [Related]
5. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
6. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
9. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
10. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Kaplan LD; Straus DJ; Testa MA; Von Roenn J; Dezube BJ; Cooley TP; Herndier B; Northfelt DW; Huang J; Tulpule A; Levine AM
N Engl J Med; 1997 Jun; 336(23):1641-8. PubMed ID: 9171066
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
14. [Colony-stimulating factors and HIV-related neoplasms].
Valencia ME; Moreno V; Soriano V; Polo R; Verdejo J; Laguna F; González Lahoz J
An Med Interna; 1996 Jul; 13(7):317-21. PubMed ID: 8962975
[TBL] [Abstract][Full Text] [Related]
15. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
16. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
18. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
[TBL] [Abstract][Full Text] [Related]
20. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]